Santa Ana Bio, Inc.

Precision medicines for serious immune mediated diseases.

Add To Watchlist
General Information
Company Name
Santa Ana Bio, Inc.
Founded Year
2022
Location (Offices)
Alameda, United States +1
Founders / Decision Makers
Peter Emtage - Founder & CEO Danny Wells - Co-Founder and CTO
Number of Employees
38
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Series B
Social Media

Santa Ana Bio, Inc. - Company Profile

Santa Ana Bio is a Bay Area biotech startup founded in 2021 with the mission of developing precision medicines for serious immune mediated diseases. Leveraging its multiomics and protein engineering platforms, the company focuses on designing precision biologics for the treatment of patients with serious immune related diseases. In June 13, 2024, the company secured a significant $125.00M Series B investment from reputable investors including GV, Andreessen Horowitz/a16z, Access Biotechnology, and RTW Investments. Santa Ana Bio operates in the Biotechnology and Health Care industries and is headquartered in the United States. This recent investment is a testament to the confidence and support of notable investors in the potential of Santa Ana Bio's innovative approach to addressing unmet medical needs in the field of immune mediated diseases.

Taxonomy: precision medicine, immune mediated diseases, Bay Area, multiomics, protein engineering, precision biologics, autoimmune diseases, inflammatory diseases, cell profiling technologies, antibody engineering, targeted therapies

Funding Rounds & Investors of Santa Ana Bio, Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Series B $125.00M 4
GV, investor in Santa Ana Bio, Inc.'s Series B round Andreessen Horowitz/ a16z, investor in Santa Ana Bio, Inc.'s Series B round Access Biotechnology, investor in Santa Ana Bio, Inc.'s Series B round RTW Investments, investor in Santa Ana Bio, Inc.'s Series B round
13 Jun 2024
Series A $43.00M 3
GV, investor in Santa Ana Bio, Inc.'s Series A round Versant Ventures, investor in Santa Ana Bio, Inc.'s Series A round
TPG 		28 Feb 2023
Venture Round $8.02M - 01 Jun 2021

Latest News of Santa Ana Bio, Inc.

View All

No recent news or press coverage available for Santa Ana Bio, Inc..

Similar Companies to Santa Ana Bio, Inc.

View All
Synlogic - Similar company to Santa Ana Bio, Inc.
Synlogic Designed for Life
Solu Therapeutics - Similar company to Santa Ana Bio, Inc.
Solu Therapeutics Solu Therapeutics is a next-generation therapeutics focused company working to eliminate cells that drive diseases.
ENDPOINT HEALTH - Similar company to Santa Ana Bio, Inc.
ENDPOINT HEALTH Precision immunology therapies
Certa Therapeutics - Similar company to Santa Ana Bio, Inc.
Certa Therapeutics Developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases
CC Bio - Similar company to Santa Ana Bio, Inc.
CC Bio Harnessing synthetic biology for the development of novel microbiome editing therapeutics
Circle Decoration Circle Decoration

Want to dive deeper into Santa Ana Bio, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now